Light chain deposition disease

Summary

Light chain deposition disease (MONDO:0019730) is a disease and 11 clinical trials. Top therapeutic interventions include bortezomib, lenalidomide, and melphalan. A subtype of non-amyloid monoclonal immunoglobulin deposition disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 11

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	light chain deposition disease
Mondo ID	MONDO:0019730
Orphanet	93558
ICD-11	1612001446
NCIT	C7727
SNOMED CT	373604002
UMLS	C0238239
MedGen	65953
GARD	0006906
Is cancer (heuristic)	no

Also known as: Bence Jones myeloma · LCDD · Light chain disease · Light chain gammopathy · Light-chain deposition disease

Disease family

This is a subtype of non-amyloid monoclonal immunoglobulin deposition disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › leukocyte disorder › B-cell neoplasm › neoplasm of mature B-cells › plasma cell neoplasm › non-amyloid monoclonal immunoglobulin deposition disease › light chain deposition disease

Related subtypes (2): heavy chain deposition disease, light and heavy chain deposition disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 11.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	4
Not specified	3
PHASE3	2
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01169337	PHASE3	ACTIVE_NOT_RECRUITING	Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
NCT01078454	PHASE3	COMPLETED	Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
NCT00520767	PHASE2	COMPLETED	Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
NCT01849783	PHASE2	COMPLETED	Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
NCT00890747	PHASE1	COMPLETED	Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
NCT01533194	PHASE1	COMPLETED	Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT01728259	PHASE1	TERMINATED	First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
NCT03820817	PHASE1	COMPLETED	Rifaximin in Patients With Monoclonal Gammopathy
NCT03717844	Not specified	RECRUITING	Registry for Adults With Plasma Cell Disorders (PCD’s)
NCT05283993	Not specified	RECRUITING	A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
NCT01383759	Not specified	COMPLETED	Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BORTEZOMIB	4	5
LENALIDOMIDE	4	1
MELPHALAN	4	1